REFERENCES
1. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison
LL. Trends in cancer incidence among children in the U.S. Cancer 1996
August 1;78(3):532e41.
2. Ladenstein R, Potschger U, Pearson AD, Brock P, Luksch R,
Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E,
Kogner P, Schroeder H, de Lacerda AF , Beck-Popovic M, Bician P,
Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G,
Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe
Neuroblastoma Group (SIOPEN).Busulfan and melphalan versus carboplatin,
etoposide, and melphalan as high-dose chemotherapy for high-risk
neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm,
open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14.
3. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale
F, Viscardi E, Bianchi M, Prete A, Jenkner A, Luksch R, Di Cataldo A,
Favre C, D’Angelo P, Zanazzo GA, Arcamone G, Izzi GC, Gigliotti AR,
Pastore G, De Bernardi B. Improved survival of children with
neuroblastoma between 1979 and 2005: a report of the Italian
Neuroblastoma Registry. J ClinOncol. 2010 May 10;28(14):2331-8.
4. K KMatthay, J G Villablanca, R C Seeger, D O Stram, R E
Harris, N K Ramsay, P Swift, H Shimada, C T Black, G M Brodeur, R B
Gerbing, C P Reynolds. Treatment of high-risk neuroblastoma with
intensive chemotherapy, radiotherapy, autologous bone marrow
transplantation, and 13-cis-retinoicacid. Children’s Cancer Group. N
Engl J Med. 1999;341:1165–73.
5. T Philip, R Ladenstein, C Lasset, O Hartmann, J M Zucker, R
Pinkerton, A D Pearson, T Klingebiel, A Garaventa, B Kremens, J L
Bernard, G Rosti, F Chauvin. 1070 myeloablative megatherapy procedures
followed by stem cell rescue for neuroblastoma: 17 years of European
experience and conclusions. European Group for Blood and Marrow
Transplant Registry Solid Tumour Working Party. Eur J Cancer.
1997;33:2130–5.
6. A Suc, J Lumbroso, H Rubie, J M Hattchouel, A Boneu, C
Rodary, A Robert, O Hartmann. Metastatic neuroblastoma in children older
than one year: prognostic significance of the initial
metaiodobenzylguanidinescan and proposal for a scoring system. Cancer
1996 February 15;77(4):805-11.
7. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S,
Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H,
Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D,
Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK.
131I-metaiodobenzylguanidine with intensive chemotherapy and autologous
stem cell transplantation for high-risk neuroblastoma. A new approach to
neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow
Transplant. 2015 Apr;21(4):673-81.
8. Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK,
Berthold F, van Noesel MM, Caron HN, Tytgat GA. Feasibility, toxicity
and response of upfront metaiodobenzylguanidine therapy followed by
German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly
diagnosed stage 4 neuroblastoma patients. Eur J Cancer. 2017
May;76:188-196.
9. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A,
Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan,
melphalan and autologous stem cell transplantation for refractory
neuroblastoma. Pediatr Blood Cancer. 2013 May;60(5):879-84.
10. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V,
Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F.Revisions
of the international criteria for neuroblastoma diagnosis, staging, and
response to treatment. J Clin Oncol. 1993 Aug;11(8):1466-77.
11. Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Publish Date: November 27, 2017. Bethesda, MD: National Institutes of
Health.
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
12. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB,
Braine HG, Vogelsang
GB, Sensenbrenner
LL, Santos
GW, SaralR. Veno-occlusive disease of the liver following bone marrow
transplantation. Transplantation 1987; 44: 778–783.
13. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED.
Veno-occlusive disease of the liver after bone marrow transplantation:
diagnosis, incidence, and predisposing factors. Hepatology 1984; 4:
116–122.
14. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B,
Schilling FH, Simon T. Long-term outcomes of the GPOH NB97 trial for
children with high-risk neuroblastoma comparing high-dose chemotherapy
with autologous stem cell transplantation and oral chemotherapy as
consolidation. Br J Cancer. 2018 Aug;119(3):282-290.
15. SIOP EUROPA NEUROBLASTOMA, Protocollo
NB-AR-01http://www.chped.it/gico/PRNB.pdf
16. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G; EANM.
EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG)
therapy. Eur J NuclMedMol Imaging. 2008;35(5):1039‐1047
17. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London
WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR,
Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification
and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep
20;33(27):3008-17.
18. R J Hutchinson, J C Sisson, J S Miser, K R Zasadny, D P
Normolle, B L Shulkin, I R Francis, D M Wieland, B Shapiro. Long-term
results of [131I]metaiodobenzylguanidine treatment of refractory
advanced neuroblastoma. J Nucl Biol Med. 1991;35:237–240.
19. Voûte PA, Hoefnagel CA, de Kraker J, Valdes Olmos R, Bakker
DJ, van de Kleij AJ. Results of treatment with 131
I-metaiodobenzylguanidine in patients with neuroblastoma. Future
projects of zetotherapy. ProgClinBiol Res. 1991;366:439–445.
20. Garaventa A, Pianca C, Conte M, Nigro M, De Bernardi B,
Claudiani F, Stimamiglio P, Bertolazzi L, Cabria M, Villavecchia GP, et
al. Place of meta-[131I]iodobenzylguanidine in the treatment of
neuroblastoma: the Genoa experience. Q J Nucl Med. 1995;39:58–60.
21. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S,
Villavecchia GP, Bertolazzi C, Cabria M, De Bernardi B. Megatherapy
combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with
haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow
Transplant. 2001 Mar;27(6):571-4.
22. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS,
Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose
escalation of 131I-metaiodobenzylguanidine with autologous bone marrow
support in refractory neuroblastoma. J ClinOncol. 1998;16:229–236.
23. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jürgens H,
Lang P, Niethammer D, Rath B, Handgretinger R. Treatment of
neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose
chemotherapy and immunotherapy. A pilot study. Eur J Cancer.
1998;34:1398–1402.
24. GazeMN, Gains JE, Walker C, Bomanji JB. Optimization of
molecular radiotherapy with [131I]-meta Iodobenzylguanidine for
high-risk neuroblastoma. Q J Nucl Med Mol Imaging. 2013;57:66–78.
25.Gaze
MN, Wheldon TE, O’Donoghue JA, Hilditch TE, McNee
SG, Simpson
E, Barrett
A.Multi-modality megatherapy with [131I]meta-iodobenzylguanidine,
high-dose melphalan and total-body irradiation with bone marrow rescue:
feasibility study of a new strategy for advanced neuroblastoma.
Eur J
Cancer. 1995;31A(2):252-6.
26. Matthay KK, Tan JC, Villablanca JG, YanikA, Veatch J, Franc
B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Phase
I dose escalation of iodine-131-metaiodobenzylguanidine with
myeloablative chemotherapy and autologous stem-cell transplantation in
refractory neuroblastoma: a new approach to Neuroblastoma Therapy
Consortium Study. J Clin Oncol. 2006;24:500–506.
27. Lee JW, Lee S, Cho HW, Ma Y, Yoo KH, Sung KW, Koo HH, Cho
EJ, Lee SK, Lim DH. Incorporation of high-dose
131I-metaiodobenzylguanidine treatment into tandem high-dose
chemotherapy and autologous stem cell transplantation for high-risk
neuroblastoma: results of the SMC NB-2009 study. J Hematol Oncol. 2017
May 16;10(1):108.
28. French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A,
Plummer E, Matthay K. 131I-MIBG followed by consolidation with busulfan,
melphalan and autologous stem cell transplantation for refractory
neuroblastoma. Pediatr Blood Cancer. 2013 May;60(5):879-84.
29 . Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O,
Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S,
Valteau-Couanet D, Defachelles AS. Feasibility of Busulfan Melphalan and
Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or
Relapsed Metastatic Neuroblastoma: The French Experience. J. Pediatr.
Hematol Oncol. 2018 Apr 10.
30. Faraci M, Bertaina A, Luksch R, Calore E, Lanino E, Saglio
F, Prete A, Menconi M, De Simone G, Tintori V, Cesaro S, Santarone S,
Orofino MG, Locatelli F, Zecca M. Sinusoidal Obstruction
Syndrome/Veno-Occlusive Disease after Autologous or Allogenic
Hematopoietic Stem Cell Transplantation in Children: a retrospective
study of the Italian Hematology-Oncology Association-Hematopoietic Stem
Cell Transplantation Group. Biol Blood Marrow Transplant. 2019
Feb;25(2):313-320. doi: 10.1016/j.bbmt.2018.09.027. Epub 2018 Sep 26.
31. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng
SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.
Phase II study on the effect of disease sites, age, and prior therapy on
response to iodine-131-metaiodobenzylguanidine therapy in refractory
neuroblastoma. J Clin Oncol2007;25(9):1054–60.
32. Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA,
Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H,
Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett
J, Lafrance N, Babich J. Dose escalation study of no-carrier-added 131
Imetaiodobenzylguanidine for relapsed or refractory neuroblastoma: new
approaches to Neuroblastoma Therapy Consortium trial. J NuclMed 2012;
2012:1155–63.
33 . Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C,
Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G,
Claudiani F, De Bernardi B. 131 I-metaiodobenzylguanidine (131 IMIBG)
therapy for residual neuroblastoma: a mono-institutionalexperience with
43 patients. Br J Cancer 1999;81(8):1378–84
34. Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R,
Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T,
Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H,
Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ,
Lode HN. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab
beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a
multicentre, randomised, phase 3 trial. Lancet Oncol. 2018
Dec;19(12):1617-1629.
35. Peinemann F, van Dalen EC, Enk H, Tytgat GA. Anti-GD2
antibody-containing immunotherapy post-consolidation therapy for people
with high-risk neuroblastoma treated with autologous haematopoietic stem
cell transplantation. Cochrane Database Syst Rev. 2019 Apr
24;4:CD012442.